Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Why a reliable FAERS searching capability is essential for pharma companies

Posted on October 27th, 2017 by

Pharmacovigilance

In the description of the FDA Adverse Event Reporting System (FAERS), the agency states that “voluntary and mandatory reporting plays an important role in the FDA’s post-market safety monitoring.” Continue reading “Why a reliable FAERS searching capability is essential for pharma companies” »

Chemists: Unsung Innovators

Posted on October 25th, 2017 by

Chemistry

Chemistry flasks

In many people’s minds, the classic image of the chemist is still someone in a lab coat standing over a burner, while chemistry itself tends to evoke thoughts of equations on chalkboards and fluids in beakers. But the reality is that these images are a bit outdated Continue reading “Chemists: Unsung Innovators” »

The Five Most-Talked about Zika Articles in 2017

Posted on October 23rd, 2017 by

Pharma R&D

Mosquito Zika

A widespread outbreak in 2015 had people across the globe concerned about Zika (ZIKV), an infectious disease mainly spread through mosquito bites. In 2016 we took a look at some of the top scientific research about the virus being shared onlineContinue reading “The Five Most-Talked about Zika Articles in 2017” »

Big Data vs. Infectious Disease

Posted on October 20th, 2017 by

Pharma R&D

syringe-1884779_1920-450x300

With the many highly effective vaccines that have been created over the last several decades, it can be easy (particularly for those in America and other developed countries) to fall into the trap of thinking that we are living in a world where infectious disease is not that big of a threat. Continue reading “Big Data vs. Infectious Disease” »

Pharma Companies United By a Need for Common Data Models

Posted on October 18th, 2017 by

Pharma R&D

Big Data

There is nothing that pharmaceutical companies guard more fiercely than their intellectual property. Devising and patenting the next big wonder drug is every company’s dream Continue reading “Pharma Companies United By a Need for Common Data Models” »

A Visit to Arctic Pharma in Oslo, Norway

Posted on October 16th, 2017 by

Pharma R&D

ship-1728078_640

In Norway, a land that evokes images of rough-hewn Scandinavians, icy natural beauty and old wooden Viking ships, there is in fact a great deal of investment currently being put into not-so-rugged things like cutting-edge new labs and state-of-the-art scientific research.

Continue reading “A Visit to Arctic Pharma in Oslo, Norway” »

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 51


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.